Abstract【Objective】To investigate the effect of tumor invasion depth and postoperative adjuvant chemotherapy on the prognosis of patients with primary bladder adenocarcinoma. 【Methods】 A total of 78 patients with primary bladder adenocarcinoma treated in our hospital were divided into survival group (49 cases) and death group (29 cases) according to the 3-year follow-up results. The age, gender, operation mode, pathological stage, pathological differentiation degree, tumor number, maximum diameter of lesion, depth of invasion, lymph node metastasis and postoperative adjuvant chemotherapy were compared between the two groups. Cox proportional hazard regression model was used to analyze the related factors affecting the prognosis of patients. 【Results】There was no significant difference in age, gender, operation mode, tumor number and maximum diameter between the two groups (P>0.05); there were significant differences in pathological stage, tumor differentiation degree, depth of invasion, postoperative adjuvant chemotherapy between survival group and death group (P<0.05); Cox proportional hazard model analysis showed that: the increased pathological stage of primary bladder adenocarcinoma, the decreased tumor differentiation and myometrial invasion were independent risk factors for poor prognosis (P<0.05). Postoperative adjuvant chemotherapy had no significant effect on the prognosis of patients (P>0.05). 【Conclusion】There are many factors that affect the prognosis of patients with primary bladder adenocarcinoma. Myometrial invasion is one of the independent risk factors. However, the effect of postoperative adjuvant chemotherapy on prognosis is not significant, which may need to be further extended for further study.
[1] 王军才, 高卫军. 根治性膀胱切除术配合辅助化疗治疗膀胱癌的临床疗效及其多变量竞争风险分析[J].国际泌尿系统杂志, 2017, 37(3):324-327. [2] 粟周华. 肌层浸润性膀胱癌保留膀胱术后用不同辅助治疗方法的临床疗效分析和评价[J].中国现代医生, 2017, 55(5):41-44. [3] Kim HS, Chang WJ, Kwak C, et al. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials[J].Oncotarget,2017, 8(46):81204-81214. [4] Haque W, Lewis GD, Verma V, et al. The role of adjuvant chemotherapy in locally advanced bladder cancer[J].Acta Oncol,2018,57(4):509-515. [5] 唐明伙, 刘强. 探讨术前新辅助化疗治疗浸润性膀胱癌的临床疗效观察[J].医药前沿, 2017, 7(16):13-14. [6] Sui W, Lim EA, Joel Decastro G, et al. Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy[J].Bladder Cancer,2017, 3(3):181-189. [7] Cienfuegos JA, Martínez P, Baixauli J, et al. Perineural invasion is a major prognostic and predictive factor of response to adjuvant chemotherapy in stage Ⅰ-Ⅱ colon cancer[J].Ann Surg Oncol,2017, 24(4):1077-1084. [8] Gao P. Impact of timing of adjuvant chemotherapy on survival in stage Ⅲ colon cancer: a population-based study[J].BMC Cancer,2018, 18(1):234-235. [9] 鲁宏磊, 张志, 刘洋, 等. 根治性膀胱切除术后回肠与乙状结肠2种原位新膀胱术的临床疗效观察[J].临床泌尿外科杂志, 2018, 289(01):76-79,83. [10] Mantripragada KC, Hamid F, Shafqat H, et al. Adjuvant therapy for resected gallbladder cancer:analysis of the national cancer data base[J].J Natl Cancer Inst,2016,109(2):djw202.
2020, Vol. 37 
